5.80
Vir Biotechnology Inc stock is traded at $5.80, with a volume of 1.18M.
It is down -3.97% in the last 24 hours and up +13.06% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$6.04
Open:
$6.005
24h Volume:
1.18M
Relative Volume:
0.90
Market Cap:
$805.72M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.4796
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+1.22%
1M Performance:
+13.06%
6M Performance:
+9.85%
1Y Performance:
-20.98%
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VIR
Vir Biotechnology Inc
|
5.80 | 839.06M | 62.04M | -533.34M | -473.07M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-03-25 | Initiated | Evercore ISI | Outperform |
Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Sep-14-22 | Initiated | SVB Leerink | Outperform |
Sep-09-22 | Initiated | Morgan Stanley | Underweight |
Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
Oct-05-20 | Initiated | BofA Securities | Buy |
Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
Aug-20-20 | Initiated | Needham | Buy |
Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-14-19 | Initiated | Robert W. Baird | Neutral |
Nov-05-19 | Initiated | Barclays | Overweight |
Nov-05-19 | Initiated | Cowen | Outperform |
Nov-05-19 | Initiated | Goldman | Buy |
Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Endurance (Cayman) Ltd Svf Sells 466,242 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
What institutional flow reveals about Vir Biotechnology Inc.Stop Loss & Free Weekly Watchlist of Top Performers - newser.com
Study launches of VIR-5500 combined with ARPIs in mCRPC - Urology Times
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTE - PharmiWeb.com
Vir Biotechnology announces first patient dosed in part 3 of phase 1 trial - MarketScreener
Vir Biotechnology doses first patient in prostate cancer combo trial - Investing.com
Vir Biotechnology (VIR) Advances Prostate Cancer Treatment with VIR-5500 Trial - GuruFocus
Vir Biotechnology stock rises as company doses first patient in prostate cancer trial - Investing.com Canada
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer - Business Wire
Should You Allocate More Funds to DCX Systems Limited in YEARResistance Breakout Alerts & Accelerated Capital Growth - earlytimes.in
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? - Nasdaq
Vir Biotechnology (NASDAQ:VIR) Trading Up 9.7%Here's What Happened - MarketBeat
What analysts say about Vir Biotechnology Inc stockInsider Trading Compliance & Exceptional Return Opportunities - earlytimes.in
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025 - BioSpace
Vir Biotechnology to present hepatitis delta treatment results at liver meeting - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $2,503,901.52 in Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 73,955 Shares - MarketBeat
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liv - PharmiWeb.com
Vir Biotechnology to present hepatitis delta treatment results at liver meeting By Investing.com - Investing.com South Africa
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting - Business Wire
Using AI based signals to follow Vir Biotechnology Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Price momentum metrics for Vir Biotechnology Inc. explainedWeekly Trade Analysis & Safe Entry Point Identification - newser.com
Is Vir Biotechnology Inc. a candidate for recovery playPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Clarius Group LLC Purchases 560,342 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 S - PharmiWeb.com
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025 - GlobeNewswire
Can machine learning forecast Vir Biotechnology Inc. recoveryWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Vir Biotechnology Shares Rise After Upgrade From BofA Securities - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gains Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Short Interest & Entry and Exit Point Strategies - خودرو بانک
Earnings Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Trade Ideas & High Return Trade Opportunity Guides - خودرو بانک
Goldman Sachs Group Inc. Boosts Holdings in Vir Biotechnology, Inc. $VIR - MarketBeat
Custom watchlist performance reports with Vir Biotechnology Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - newser.com
Fed Meeting: Is Vir Biotechnology Inc stock a smart retirement pickWeekly Stock Recap & Proven Capital Preservation Tips - خودرو بانک
Retail Surge: Is ABRPRF stock risky to hold nowJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - khodrobank.com
Vir Biotechnology's (VIR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Trading Down 4.7%Here's Why - MarketBeat
Technical Analysis: What are the analyst revisions for Vir Biotechnology Inc.Is LBTYB stock a good investment in YEARMarket Rally & Stepwise Entry and Exit Trade Signals - خودرو بانک
Aug Highlights: Is Vir Biotechnology Inc stock influenced by commodity pricesJuly 2025 Pullbacks & Low Risk Entry Point Tips - خودرو بانک
Vir Biotechnology’s SWOT analysis: undervalued stock with potential in HDV and oncology - Investing.com Nigeria
Aug Shorts: How cyclical is Vir Biotechnology Incs revenue streamInflation Watch & Weekly High Return Forecasts - خودرو بانک
Returns Recap: Is Vir Biotechnology Inc. stock a smart retirement pickJuly 2025 Action & Accurate Buy Signal Alerts - خودرو بانک
Companies Like Vir Biotechnology (NASDAQ:VIR) Could Be Quite Risky - 富途牛牛
Aug Patterns: How cyclical is Vir Biotechnology Incs revenue streamBear Alert & Accurate Entry/Exit Alerts - khodrobank.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 07 '25 |
Sale |
5.60 |
72,133 |
404,154 |
16,087,611 |
SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 03 '25 |
Sale |
5.56 |
450,342 |
2,501,785 |
16,233,699 |
SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 06 '25 |
Sale |
5.69 |
73,955 |
420,641 |
16,159,744 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):